DNA and Modified Vaccinia Virus Ankara Vaccines Encoding Multiple Cytotoxic and Helper T-lymphocyte Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) Are Safe but Weakly Immunogenic in HIV-1-uninfected, Vaccinia Virus-naive Adults

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2012 Mar 9

PMID 22398243

Citations 14

Authors

Geoffrey J Gorse

Mark J Newman

Allan deCamp

Christine Mhorag Hay

Stephen C De Rosa

Elizabeth Noonan

Brian D Livingston

Jonathan D Fuchs

Spyros A Kalams

Farah L Cassis-Ghavami

Affiliations

Soon will be listed here.

Abstract

We evaluated a DNA plasmid-vectored vaccine and a recombinant modified vaccinia virus Ankara vaccine (MVA-mBN32), each encoding cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) in a randomized, double-blinded, placebo-controlled trial in 36 HIV-1-uninfected adults using a heterologous prime-boost schedule. HIV-1-specific cellular immune responses, measured as interleukin-2 and/or gamma interferon production, were induced in 1 (4%) of 28 subjects after the first MVA-mBN32 immunization and in 3 (12%) of 25 subjects after the second MVA-mBN32 immunization. Among these responders, polyfunctional T-cell responses, including the production of tumor necrosis factor alpha and perforin, were detected. Vaccinia virus-specific antibodies were induced to the MVA vector in 27 (93%) of 29 and 26 (93%) of 28 subjects after the first and second immunizations with MVA-mBN32. These peptide-based vaccines were safe but were ineffective at inducing HIV-1-specific immune responses and induced much weaker responses than MVA vaccines expressing the entire open reading frames of HIV-1 proteins.

Citing Articles

Design and evaluation of a multi-epitope DNA vaccine against HPV16.

Zhu L, Cui X, Yan Z, Tao Y, Shi L, Zhang X Hum Vaccin Immunother. 2024; 20(1):2352908.

PMID: 38780076 PMC: 11123455. DOI: 10.1080/21645515.2024.2352908.

Cervico-Vaginal Inflammatory Cytokine and Chemokine Responses to Two Different SIV Immunogens.

Toledo N, Li H, Omange R, Dacoba T, Crecente-Campo J, Schalk D Front Immunol. 2020; 11:1935.

PMID: 32983121 PMC: 7477078. DOI: 10.3389/fimmu.2020.01935.

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.

Churchyard G, Mlisana K, Karuna S, Williamson A, Williamson C, Morris L PLoS One. 2016; 11(9):e0161753.

PMID: 27583368 PMC: 5008759. DOI: 10.1371/journal.pone.0161753.

The evolution of poxvirus vaccines.

Sanchez-Sampedro L, Perdiguero B, Mejias-Perez E, Garcia-Arriaza J, Di Pilato M, Esteban M Viruses. 2015; 7(4):1726-803.

PMID: 25853483 PMC: 4411676. DOI: 10.3390/v7041726.

Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Altenburg A, Kreijtz J, de Vries R, Song F, Fux R, Rimmelzwaan G Viruses. 2014; 6(7):2735-61.

PMID: 25036462 PMC: 4113791. DOI: 10.3390/v6072735.

References

Vollmar J, Arndtz N, Eckl K, Thomsen T, Petzold B, Mateo L . Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine. 2005; 24(12):2065-70. DOI: 10.1016/j.vaccine.2005.11.022. View

Radcliffe J, Roddick J, Friedmann P, Stevenson F, Thirdborough S . Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells. J Immunol. 2006; 177(10):6626-33. DOI: 10.4049/jimmunol.177.10.6626. View

Doria-Rose N, Ohlen C, Polacino P, Pierce C, Hensel M, Kuller L . Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol. 2003; 77(21):11563-77. PMC: 229261. DOI: 10.1128/jvi.77.21.11563-11577.2003. View

Belshe R, Stevens C, Gorse G, Buchbinder S, Weinhold K, SHEPPARD H . Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis. 2001; 183(9):1343-52. DOI: 10.1086/319863. View

de Bruyn G, Rossini A, Chiu Y, Holman D, Elizaga M, Frey S . Safety profile of recombinant canarypox HIV vaccines. Vaccine. 2004; 22(5-6):704-13. DOI: 10.1016/j.vaccine.2003.08.023. View

Shulman N, Bellew M, Snelling G, Carter D, Huang Y, Li H . Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials. Cytometry A. 2008; 73(9):847-56. PMC: 2591089. DOI: 10.1002/cyto.a.20600. View

Subbramanian R, Kuroda M, Charini W, Barouch D, Costantino C, Santra S . Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys. J Virol. 2003; 77(18):10113-8. PMC: 224609. DOI: 10.1128/jvi.77.18.10113-10118.2003. View

Barouch D, Santra S, Kuroda M, Schmitz J, Plishka R, Buckler-White A . Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol. 2001; 75(11):5151-8. PMC: 114920. DOI: 10.1128/JVI.75.11.5151-5158.2001. View

Dubey S, Clair J, Fu T, Guan L, Long R, Mogg R . Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr. 2007; 45(1):20-7. DOI: 10.1097/QAI.0b013e3180377b5b. View

10.

Mumper R, Duguid J, Anwer K, Barron M, Nitta H, Rolland A . Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle. Pharm Res. 1996; 13(5):701-9. DOI: 10.1023/a:1016039330870. View

11.

Drexler I, Staib C, Kastenmuller W, Stevanovic S, Schmidt B, Lemonnier F . Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A. 2003; 100(1):217-22. PMC: 140931. DOI: 10.1073/pnas.262668999. View

12.

Barouch D, Santra S, Schmitz J, Kuroda M, Fu T, Wagner W . Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000; 290(5491):486-92. DOI: 10.1126/science.290.5491.486. View

13.

Carroll M, Moss B . Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 1997; 238(2):198-211. DOI: 10.1006/viro.1997.8845. View

14.

Fu T, Ulmer J, Caulfield M, Deck R, Friedman A, Wang S . Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med. 1997; 3(6):362-71. PMC: 2230213. View

15.

Hanke T, McMichael A, Dorrell L . Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol. 2006; 88(Pt 1):1-12. DOI: 10.1099/vir.0.82493-0. View

16.

Shen X, Wong S, Buck C, Zhang J, Siliciano R . Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol. 2002; 169(8):4222-9. DOI: 10.4049/jimmunol.169.8.4222. View

17.

Allen T, Vogel T, Fuller D, Mothe B, Steffen S, Boyson J . Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol. 2000; 164(9):4968-78. DOI: 10.4049/jimmunol.164.9.4968. View

18.

Pilgrim J, Gerostamoulos D, Drummer O, Bollmann M . Involvement of amphetamines in sudden and unexpected death. J Forensic Sci. 2009; 54(2):478-85. DOI: 10.1111/j.1556-4029.2008.00949.x. View

19.

Ishioka G, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M . Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol. 1999; 162(7):3915-25. View

20.

Perfetto S, Chattopadhyay P, Lamoreaux L, Nguyen R, Ambrozak D, Koup R . Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J Immunol Methods. 2006; 313(1-2):199-208. DOI: 10.1016/j.jim.2006.04.007. View